Homologous recombination for universal donor cells and chimeric mammalian hosts

US6514752B1 · kind B1 · utility

Assignee

• Cell Genesys, Inc. · US

Inventors

• Raju Kucherlapati · Darien, US
• Beverly Koller · Carrboro, US
• Oliver Smithies · Durham, US
• Robert B. Dubridge · Belmont, US
• Gary Greenburg · Redwood City, US
• Daniel J. Capon · Hillsborough, US
• Steven R. Williams · Colorado Springs, US
• Mariona Lourdes Arbones De Rafael · Barcelona, ES

Key dates

• Filing date: May 18, 1995
• Grant date: Feb 4, 2003
• Expiry date: May 18, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A01K2267/0381
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the &bgr;2-microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.